Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RLMD Relmada Therapeutics, Inc.

交易中 12-19 10:54:51 EST

0.3610

+0.0077

+2.18%

最高0.3700	最低0.3504	成交量26.33万
今开0.3585	昨收0.3533	日振幅5.55%
总市值1,089万	流通市值994.21万	总股本3,017万
成交额9.47万	换手率0.96%	流通股本2,754万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":0.361,"timestamp":1734623651565,"preClose":0.3533,"halted":0,"volume":263271,"delay":0,"floatShares":27540528,"shares":30174202,"eps":-2.869047,"marketStatus":"交易中","marketStatusCode":2,"change":0.0077,"latestTime":"12-19 10:54:51 EST","open":0.3585,"high":0.37,"low":0.3504,"amount":94746.0991155,"amplitude":0.055477,"askPrice":0.3615,"askSize":175,"bidPrice":0.3537,"bidSize":773,"shortable":3,"etf":0,"ttmEps":-2.869047,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734642000000},"adr":0,"adjPreClose":0.3533,"preHourTrading":{"tag":"盘前","latestPrice":0.3543,"preClose":0.3533,"latestTime":"08:46 EST","volume":3154,"amount":1114.91572348,"timestamp":1734615983539},"postHourTrading":{"tag":"盘后","latestPrice":0.35,"preClose":0.3533,"latestTime":"19:58 EST","volume":45561,"amount":16021.44661,"timestamp":1734569904849},"volumeRatio":0.840737,"impliedVol":1.6162,"impliedVolPercentile":0.5159},"requestUrl":"/m/hq/s/RLMD","defaultTab":"news","newsList":[{"id":"2490868978","title":"Relmada Therapeutics, Inc.盘中异动 早盘快速下挫5.87%报0.442美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490868978?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:31","pubTimestamp":1733927461,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时31分，Relmada Therapeutics, Inc.股票出现波动，股价大幅下跌5.87%。截至发稿，该股报0.442美元/股，成交量6.6861万股，换手率0.22%，振幅0.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Candel Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Synlogic, Inc.涨幅较大，Silexion Therapeutics Corp、Candel Therapeutics, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为365.60%、100.62%、97.27%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、Synlogic, Inc.、Bioline Rx Ltd，振幅分别为7.69%、6.21%、5.03%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223101ab6fc977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223101ab6fc977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2490749087","title":"BUZZ-Relmada Therapeutics 探索战略选择；股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2490749087","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490749087?lang=zh_cn&edition=full","pubTime":"2024-12-09 23:58","pubTimestamp":1733759914,"startTime":"0","endTime":"0","summary":"12月9日 -  ** 药物开发商Relmada Therapeutics RLMD.O股价上涨4.9%至48美分  ** 该公司称，在终止了  两项为开发抑郁症药物而计划的后期研究后，它已开始探索战略替代方案 ** 公司计划考虑多种选择，包括出售公司资产、出售公司、合并或反向合并；并补充说，公司尚未制定完成评估过程的时间表。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4T3NA18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2490729023","title":"Relmada终止抑郁症药物后期试验，探索出售事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2490729023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490729023?lang=zh_cn&edition=full","pubTime":"2024-12-09 20:39","pubTimestamp":1733747982,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透12月9日 - Relmada Therapeutics   周一表示，它将中止为开发抑郁症药物而计划的两项后期研究，并探索包括出售在内的战略替代方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2489483099","title":"美国研究综述-Autozone, Costco Wholesale, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2489483099","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489483099?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:19","pubTimestamp":1733383180,"startTime":"0","endTime":"0","summary":"    路透社12月5日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Autozone、好市多批发公司和 Salesforce。要闻  * Autozone Inc   ：摩根大通将目标价从3275美元上调至3400美元 * 好市多批发公司  ：摩根大通将目标价从945美元上调至1090美元 * Salesforce Inc   ：汇丰银行将目标价从326美元上调至413美元 以下是路透社周四报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCNO","CHWY","CHPT","DLTR","FL","EW","CDMO","COST","RLMD","KMX","ASB","CCRN","CRM","CPB","GXO","CXM","PRO","AZO"],"gpt_icon":1},{"id":"2489055115","title":"嗡嗡声--美国股票走势-纳米核能、捷蓝航空、越野飞机","url":"https://stock-news.laohu8.com/highlight/detail?id=2489055115","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489055115?lang=zh_cn&edition=full","pubTime":"2024-12-05 00:05","pubTimestamp":1733328315,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI上涨0.31%，报44,846.04点；标准普尔500指数.SPX上涨0.29%，报6,067.26点；纳斯达克综合指数.IXIC上涨0.84%，报19,644.70点。标准普尔 500 指数.PG.INX百分比涨幅前三名是： ** Salesforce Inc CRM.N，上涨 8.8. ** Vistra Corp VST.N，上涨 5.7 标准普尔 500 指数.PL.INX跌幅前三名： ** Globe Life Inc GL.N，下跌 8.2. 由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3S3N5182:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBRL","SG9999014021.USD","NVAX","SG9999015978.USD","GL","LU1951200564.SGD","BK4561","IE00BMPRXR70.SGD","CRM","LU1323610961.USD","CCRN","MSM","NNE","ORIS","LU2362541513.USD","SRM","LU2237443895.HKD","LU0251131958.USD","RLMD","LU0792757196.USD","BK4196","PSTG","MKTX","CURV","BK4596","GM","LU0056508442.USD","ADM","HRTX","LU1571399168.USD","AES","RBOT","BK4155","CYCN","JBLU","LU2290526834.HKD","LU0642271901.SGD","AVIR","LEV","LLY","CRGY","BK4213","BK4527","DLTR","VST"],"gpt_icon":1},{"id":"2488197547","title":"Relmada Therapeutics, Inc.盘中异动 大幅下挫76.50%报0.651美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488197547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488197547?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:32","pubTimestamp":1733322732,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日22时32分，Relmada Therapeutics, Inc.股票出现波动，股价快速跳水76.50%。截至发稿，该股报0.651美元/股，成交量392.623万股，换手率13.01%，振幅2.74%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Cyclerion Therapeutics, Inc.、Heron Therapeutics, Inc.、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Cyclerion Therapeutics, Inc.、Can Fite Biopharma Ltd、Windtree Therapeutics, Inc.较为活跃，换手率分别为1238.61%、191.03%、111.34%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Heron Therapeutics, Inc.、Eterna Therapeutics Inc.，振幅分别为53.42%、27.97%、13.56%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204223212a26c5dfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204223212a26c5dfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","RLMD","BK4007"],"gpt_icon":0},{"id":"2488919496","title":"嗡嗡声--美国股票走势-礼来、通用汽车、美元树","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919496","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488919496?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:24","pubTimestamp":1733322276,"startTime":"0","endTime":"0","summary":".N  ** Novavax Inc NVAX.O:BUZZ - 因向诺和诺德出售2亿美元捷克生产基地而上涨 nL3N3N50NS  ** Heron Therapeutics Inc HRTX.O:BUZZ - 因法院对 Cinvanti 专利的有利裁决而上涨。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3S3N511Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014898.SGD","LU1868836914.USD","GM","SG9999015945.SGD","RLMD","HRTX","CRGY","LU2237443382.USD","BK4504","LLY","LU1046421795.USD","BK4213","SGXZ81514606.USD","MRVL","LU0130102774.USD","LU0251142724.SGD","LU0070302665.USD","LU1803068979.SGD","CRM","BK4559","BK4579","BK4538","LU2491050071.SGD","IE0009355771.USD","BK4516","LU0456855351.SGD","LU0345770308.USD","SG9999018865.SGD","LU0320765489.SGD","LU0187121727.USD","LU0385154629.USD","LU1064131342.USD","LU2236285917.USD","LU2023250504.SGD","LU0251131958.USD","BK4007","DLTR","LU0122379950.USD","LU0096364046.USD","BK4581","IE00BQXX3F31.USD","LU0477156797.USD","LU2322448957.HKD","AVIR","IE00B1BXHZ80.USD","LU0689472784.USD","LU0820561909.HKD","NVAX","BK4550","LU0648001328.SGD"],"gpt_icon":1},{"id":"2488195110","title":"BUZZ-抗抑郁药物难以达到主要试验目标，Relmada Therapeutics业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195110","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488195110?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:28","pubTimestamp":1733318883,"startTime":"0","endTime":"0","summary":"12月4日 -  ** 药物开发商Relmada Therapeutics RLMD.O股价盘前下跌77.6%至62美分 ** 该公司称， ，根据独立数据监测委员会的分析，其抑郁症治疗 \"不太可能 \"达到后期试验的主要目标。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3T3N50Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2488938431","title":"分析显示，Relmada公司的抑郁症药物不太可能达到主要试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2488938431","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488938431?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:00","pubTimestamp":1733317231,"startTime":"0","endTime":"0","summary":"更新版 1-分析显示，Relmada公司的抑郁症药物不太可能达到主要试验目标第2、4段增加了详细信息，第3段引用了首席执行官的话路透社12月4日 - Relmada Therapeutics公司RLMD.O周三援引独立数据监测委员会的分析称，该公司的抑郁症治疗 \"不太可能 \"达到后期试验的主要目标。截至9月30日，Relmada公司拥有约5410万美元的现金及其等价物。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3T3N50WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2488607491","title":"Relmada称独立分析显示抑郁症治疗不太可能达到主要试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2488607491","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488607491?lang=zh_cn&edition=full","pubTime":"2024-12-04 20:42","pubTimestamp":1733316139,"startTime":"0","endTime":"0","summary":"Relmada称独立分析显示抑郁症治疗不太可能达到主要试验目标路透社12月4日 - Relmada Therapeutics RLMD.O周三表示，根据独立数据监测委员会的分析，该公司治疗重度抑郁症的疗法 \"不太可能 \"达到后期试验的主要目标。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3T3N50VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2488901946","title":"Relmada Therapeutics, Inc.盘中异动 早盘股价大跌5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488901946","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488901946?lang=zh_cn&edition=full","pubTime":"2024-12-03 22:40","pubTimestamp":1733236803,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日22时40分，Relmada Therapeutics, Inc.股票出现波动，股价大幅下挫5.47%。截至发稿，该股报3.11美元/股，成交量8792股，换手率0.03%，振幅4.26%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Janux Therapeutics, Inc.、Coherus Biosciences, Inc.、Cytomx Therapeutics, Inc.涨幅较大，Nls Pharmaceutics Ltd.、Purple Biotech Ltd、Senti Biosciences, Inc.较为活跃，换手率分别为132.48%、73.75%、58.60%，振幅较大的相关个股有Coherus Biosciences, Inc.、Senti Biosciences, Inc.、Alpha Tau Medical Ltd C/Wts ，振幅分别为24.09%、23.90%、15.00%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203224003abf2fcd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203224003abf2fcd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2485261287","title":"Relmada Therapeutics, Inc.盘中异动 股价大涨8.00%报2.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261287?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:44","pubTimestamp":1732286641,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时44分，Relmada Therapeutics, Inc.股票出现异动，股价快速上涨8.00%。截至发稿，该股报2.97美元/股，成交量2168股，换手率0.01%，振幅8.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Virpax Pharmaceuticals, Inc.、Exicure, Inc.涨幅较大，Virpax Pharmaceuticals, Inc.、Exicure, Inc.、Molecular Templates, Inc.较为活跃，换手率分别为900.70%、81.41%、69.14%，振幅较大的相关个股有Virpax Pharmaceuticals, Inc.、Exicure, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为44.82%、33.24%、30.69%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224401a24e263c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224401a24e263c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2484674900","title":"Relmada Therapeutics, Inc.盘中异动 大幅拉升5.81%报3.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484674900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484674900?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:50","pubTimestamp":1731941442,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时50分，Relmada Therapeutics, Inc.股票出现波动，股价急速拉升5.81%。截至发稿，该股报3.19美元/股，成交量2.0748万股，换手率0.07%，振幅7.11%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Hcw Biologics Inc.、冠科美博、Fate Therapeutics, Inc.涨幅较大，Tharimmune, Inc.、Hcw Biologics Inc.、冠科美博较为活跃，换手率分别为546.77%、384.20%、286.53%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Fate Therapeutics, Inc.，振幅分别为118.81%、71.83%、62.38%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118225043971a7302&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118225043971a7302&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RLMD","LENZ","BK4007"],"gpt_icon":0},{"id":"2484051028","title":"Relmada Therapeutics, Inc.2024财年第三财季实现净利润-21.73百万美元，同比增加1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484051028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484051028?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731773006,"startTime":"0","endTime":"0","summary":"11月17日，Relmada Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-21.73百万美元，同比增加1.23%；其中营业收入为0.00美元，每股基本收益为-0.72美元。从资产负债表来看，Relmada Therapeutics, Inc.总负债8.10百万美元，其中短期债务0.00美元，资产负债比为6.88，流动比率为6.89。机构评级：截至2024年11月17日，当前有4家机构对Relmada Therapeutics, Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为2.00美元，最高目标价为23.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000438a23e0727&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RLMD","LENZ"],"gpt_icon":0},{"id":"2482455678","title":"Relmada Therapeutics Inc 报告本季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2482455678","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482455678?lang=zh_cn&edition=full","pubTime":"2024-11-09 05:07","pubTimestamp":1731100039,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc 报告本季度业绩 - 收益摘要Relmada Therapeutics Inc RLMD.OQ报告本季度调整后每股亏损72美分，高于去年同期的每股-73美分。四位分析师对该季度的平均预期是每股亏损 64 美分。Relmada Therapeutics Inc 报告的季度每股收益为亏损 72 美分。该公司当季亏损 2173 万美元。Relmada Therapeutics Inc 本季度股价上涨了 0.6%，今年迄今为止亏损了 21.3%。华尔街对 Relmada Therapeutics Inc 的 12 个月目标价中位数为 11.50 美元。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4S3MF2LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2481565120","title":"Relmada Therapeutics Inc   预计每股亏损64美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481565120","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481565120?lang=zh_cn&edition=full","pubTime":"2024-11-05 06:20","pubTimestamp":1730758813,"startTime":"0","endTime":"0","summary":"   * Relmada Therapeutics Inc    预计在11月6日公布截至2024年9月30日的财报时，季度营收将不会有任何变化(预计)。*    * LSEG 的分析师平均预计 Relmada Therapeutics Inc 每股亏损 64 美分。* 华尔街对 Relmada Therapeutics Inc 的 12 个月目标价中位数为 11.50 美元，高于其上一次收盘价 3.49 美元。11月4日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","LENZ"],"gpt_icon":0},{"id":"2477598573","title":"Relmada Therapeutics, Inc.盘中异动 快速跳水6.47%报3.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477598573","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477598573?lang=zh_cn&edition=full","pubTime":"2024-10-22 22:45","pubTimestamp":1729608355,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日22时45分，Relmada Therapeutics, Inc.股票出现波动，股价急速下跌6.47%。截至发稿，该股报3.40美元/股，成交量2.7366万股，换手率0.09%，振幅2.48%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.43%。其相关个股中，Ensysce Biosciences, Inc.、Genprex, Inc.、Sangamo Therapeutics, Inc.涨幅较大，Genprex, Inc.、Ensysce Biosciences, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为4212.97%、3575.74%、1923.87%，振幅较大的相关个股有Ensysce Biosciences, Inc.、Aptevo Therapeutics Inc.、Genprex, Inc.，振幅分别为165.44%、99.41%、81.46%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022224556a1e2d34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022224556a1e2d34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RLMD","LENZ","BK4007"],"gpt_icon":0},{"id":"2475685750","title":"Relmada Therapeutics, Inc.盘中异动 快速上涨5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475685750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475685750?lang=zh_cn&edition=full","pubTime":"2024-10-15 21:36","pubTimestamp":1728999410,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日21时36分，Relmada Therapeutics, Inc.股票出现异动，股价急速上涨5.97%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Apollomics Inc C/Wts 01/04/2028 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Lipella Pharmaceuticals Inc.、Enveric Biosciences, Inc.、Gritstone Bio, Inc.较为活跃，换手率分别为249.50%、169.92%、144.09%，振幅较大的相关个股有Gritstone Bio, Inc.、Meiragtx Holdings Plc、Bright Minds Biosciences Inc.，振幅分别为29.63%、15.52%、14.05%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015213651971a05ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015213651971a05ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","RLMD","BK4007"],"gpt_icon":0},{"id":"2472952294","title":"Relmada Therapeutics, Inc.盘中异动 早盘大幅拉升8.54%报3.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472952294","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472952294?lang=zh_cn&edition=full","pubTime":"2024-10-04 21:32","pubTimestamp":1728048741,"startTime":"0","endTime":"0","summary":"北京时间2024年10月04日21时32分，Relmada Therapeutics, Inc.股票出现波动，股价急速上涨8.54%。截至发稿，该股报3.56美元/股，成交量1681股，换手率0.01%，振幅0.00%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Aditxt, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Oculis Holding Ag C/Wts 06/03/2028 涨幅较大，Aditxt, Inc.、Elevai Labs, Inc.、Theriva Biologics, Inc.较为活跃，换手率分别为1532.75%、16.75%、16.26%，振幅较大的相关个股有Aditxt, Inc.、Pharmacyte  Biotech, Inc.、Estrella Immunopharma, Inc.，振幅分别为16.49%、10.98%、9.01%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100421322198e3a94a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100421322198e3a94a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RLMD","LENZ","BK4007"],"gpt_icon":0},{"id":"2460001085","title":"Relmada Therapeutics, Inc.盘中异动 急速下跌5.82%报2.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460001085","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460001085?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:35","pubTimestamp":1724160946,"startTime":"0","endTime":"0","summary":"北京时间2024年08月20日21时35分，Relmada Therapeutics, Inc.股票出现波动，股价急速下挫5.82%。Relmada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Inmed Pharmaceuticals Inc.、泰坦制药、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Inmed Pharmaceuticals Inc.、泰坦制药、Alzamend Neuro, Inc.较为活跃，换手率分别为1812.93%、335.65%、191.34%，振幅较大的相关个股有Inmed Pharmaceuticals Inc.、Biomotion Sciences C/Wts Exp 15/08/2029 、泰坦制药，振幅分别为103.11%、78.89%、28.68%。Relmada Therapeutics, Inc.公司简介：Relmada Therapeutics Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820213546a1d53b6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820213546a1d53b6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","RLMD","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.relmada.com","stockEarnings":[{"period":"1week","weight":-0.1538},{"period":"1month","weight":-0.883},{"period":"3month","weight":-0.8991},{"period":"6month","weight":-0.8834},{"period":"1year","weight":-0.8575},{"period":"ytd","weight":-0.9147}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Relmada Therapeutics, Inc.是私人控股公司，于2004年5月注册成立。该公司是一家临床阶段的生物制药公司，致力于开发用于治疗慢性疼痛的候选药物。该公司专注于开发d-methadone（右美沙酮，REL-1017），一种N-甲基-D-天冬氨酸（NMDA）受体拮抗剂。美沙酮是一种新的化学实体，可能解决中枢神经系统（CNS）疾病和其他疾病治疗中未满足医疗需求的领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047507},{"month":2,"riseRate":0.666667,"avgChangeRate":0.107392},{"month":3,"riseRate":0.5,"avgChangeRate":-0.035153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.029344},{"month":5,"riseRate":0.428571,"avgChangeRate":0.009291},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.112899},{"month":7,"riseRate":0.714286,"avgChangeRate":0.090315},{"month":8,"riseRate":0.428571,"avgChangeRate":0.000624},{"month":9,"riseRate":0.857143,"avgChangeRate":0.103955},{"month":10,"riseRate":0.428571,"avgChangeRate":0.103531},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.078877},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.012763}],"exchange":"NASDAQ","name":"Relmada Therapeutics, Inc.","nameEN":"Relmada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Relmada Therapeutics, Inc.,RLMD,Relmada Therapeutics, Inc.股票,Relmada Therapeutics, Inc.股票老虎,Relmada Therapeutics, Inc.股票老虎国际,Relmada Therapeutics, Inc.行情,Relmada Therapeutics, Inc.股票行情,Relmada Therapeutics, Inc.股价,Relmada Therapeutics, Inc.股市,Relmada Therapeutics, Inc.股票价格,Relmada Therapeutics, Inc.股票交易,Relmada Therapeutics, Inc.股票购买,Relmada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Relmada Therapeutics, Inc.(RLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Relmada Therapeutics, Inc.(RLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}